**Background of ANXA7 Antibody**
ANXA7 (Annexin A7) is a calcium-dependent phospholipid-binding protein belonging to the annexin family, which plays roles in membrane organization, exocytosis, and intracellular signaling. It is encoded by the *ANXA7* gene and is implicated in regulating membrane fusion events, vesicle trafficking, and calcium homeostasis. ANXA7 is ubiquitously expressed but shows tissue-specific variations, with high levels in the brain, heart, and endocrine tissues.
Research highlights ANXA7's dual role in cancer. While it may act as a tumor suppressor in prostate cancer by modulating GTPase signaling pathways, its overexpression in gliomas and hepatocellular carcinoma correlates with poor prognosis, suggesting context-dependent functions. ANXA7 also interacts with signaling molecules like S100A10 and participates in apoptosis regulation.
ANXA7 antibodies are essential tools for detecting and quantifying ANXA7 expression in research. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study ANXA7's localization, expression patterns, and interactions in normal and diseased tissues. Dysregulation of ANXA7 has been linked to cancers, neurological disorders, and cardiovascular diseases, making its antibody a valuable reagent for exploring disease mechanisms or potential therapeutic targets. Commercial ANXA7 antibodies are typically validated for specificity against recombinant or endogenous proteins across species, aiding in translational research and diagnostic development.